ProTexase Therapeutics, Inc.

Saint Louis, MO · Biotech · Private

Small molecule inhibitors of serine proteases (hepsin, matriptase, HGF activator) that block hepatocyte growth factor activation and MET signaling in cancer cells

Claim this profile

Follows are private to you and power your alerts

Updated · protexase.com

Sector
Biotech
Headquarters
Saint Louis, MO
Total capital
$600K
Federal grants
$600K
2 awards · 2018–2019
Rank in peer group#173 of 502
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20182019FEDERAL ↑EQUITY ↓Cumulative $600K$300K$300K
20182019FEDERAL ↑EQUITY ↓Cumulative $600K$300K$300K

Latest events

  • Federal grantHealth and Human S · Phase I · Inhibitors of pro-HGF activation overcome resistance to anti-EGFR therapy$300K
  • Federal grantHealth and Human S · Phase I · Targeting Hepatocyte Growth Factor Processing and Activation in Lung Cancer$300K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 502 peers

Line = median

Biotech · Molecule

  • Federal grants#173 · top 34%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • AegisCN LLCSimilar federal contract value in Biotech · null in contracts
  • SAROS THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
  • Casma TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Aquavit Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
  • InVivo Therapeutics CorpSimilar federal contract value in Biotech · null in contracts
  • NodTheraSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .